Management ChangeApr 16, 2026, 07:41 AM
Xilio Therapeutics Elects Cheryl R. Blanchard to Board
AI Summary
Xilio Therapeutics, Inc. announced the election of Cheryl R. Blanchard, Ph.D., as a Class III director to its Board of Directors, effective April 15, 2026. Her term will expire at the Company's 2027 annual meeting of stockholders. Dr. Blanchard was also appointed as chair of the Compensation Committee and a member of the Audit Committee, receiving standard non-employee director compensation including cash fees and stock options.
Key Highlights
- Cheryl R. Blanchard, Ph.D., elected as a Class III director.
- Appointed chair of the Compensation Committee and member of the Audit Committee.
- Annual cash fees: $40,000 (Board), $12,000 (Comp. Chair), $7,500 (Audit Member).
- Received initial stock option grant for 10,000 shares.
- Eligible for annual 5,000-share stock option after six months.
Price Impact
More from XLO